Phaseline

Companies › Merz Pharmaceuticals

Merz Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Incobotulinumtoxina
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
SNAP25Phase 3Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain InjuryApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03992404IncobotulinumtoxinaPhase 3Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain InjuryNeurologyApr 2027

Targets

SNAP25 (1)

Companies with the same targets

AbbVie Biojiva Merz Therapeutics Ipsen Huons Biopharma Merz Aesthetics Merz North America

Companies built like this

Merz Therapeutics Sandoz Lupin Neurona Therapeutics Cytopeutics Sdn. Bhd.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.